Buparlisib

Generic Name: Buparlisib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁F_₃N_₆O_₂

CAS Number: 944396-07-0

Unique Ingredient Identifier: 0ZM2Z182GD

Background: Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Mantle Cell Lymphoma
Follicular Lymphoma
Diffuse Large B Cell Lymphoma

Interventions: Drug: Buparlisib
Drug: Ibrutinib

First Posted Date: 2016-04-29

Last Posted Date: 2022-10-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 37

Registration Number: NCT02756247

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 3 locations

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1

Terminated

Conditions: Recurrent Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma

Interventions: Drug: Buparlisib
Drug: Ibrutinib
Biological: Ofatumumab

First Posted Date: 2015-11-25

Last Posted Date: 2019-09-03

Lead Sponsor: Emory University

Target Recruit Count: 1

Registration Number: NCT02614508

Locations: 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

Phase 2

Conditions: Malignant Melanoma
Metastases

Interventions: Drug: Buparlisib

First Posted Date: 2015-05-22

Last Posted Date: 2017-05-03

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 22

Registration Number: NCT02452294

Locations: 🇩🇪
Department of Dermatology, University Hospital, Tuebingen, Germany
🇩🇪
Department of Dermatology, University Hopsital, Dresden, Germany

Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Buparlisib

First Posted Date: 2015-01-19

Last Posted Date: 2023-08-22

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 14

Registration Number: NCT02340780

Locations: 🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada

and more 3 locations

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Phase 2

Terminated

Conditions: Carcinoma, Basal Cell
Recurrent Skin Cancer
Basal Cell Nevus Syndrome
Skin Neoplasms

Interventions: Drug: Buparlisib
Drug: Sonidegib

First Posted Date: 2014-11-27

Last Posted Date: 2019-01-29

Lead Sponsor: Anne Chang

Target Recruit Count: 10

Registration Number: NCT02303041

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

Phase 1

Completed

Conditions: Advanced or Metastatic Breast Cancer

Interventions: Drug: LEE011
Drug: Buparlisib
Drug: Letrozole

First Posted Date: 2014-06-03

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT02154776

Locations: 🇺🇸
Horizon Oncology Center SC, Lafayette, Indiana, United States
🇺🇸
Medical University of South Carolina SC, Charleston, South Carolina, United States
🇺🇸
South Texas Accelerated Research Therapeutics SC, San Antonio, Texas, United States

and more 3 locations

Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Buparlisib

First Posted Date: 2014-01-29

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT02048787

Locations: 🇷🇴
Novartis Investigative Site, Bucuresti, Romania

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer
Adult Solid Neoplasm

Interventions: Drug: Buparlisib
Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Questionnaire Administration

First Posted Date: 2013-10-29

Last Posted Date: 2023-04-27

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01971489

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

Phase 1

Completed

Conditions: Recurrent Glioblastoma Multiforme

Interventions: Drug: buparlisib
Drug: carboplatin
Drug: lomustine
Drug: placebo

First Posted Date: 2013-09-04

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 35

Registration Number: NCT01934361

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 3 locations

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: buparlisib
Drug: alpelisib

First Posted Date: 2013-08-15

Last Posted Date: 2018-09-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 340

Registration Number: NCT01923168

Locations: 🇺🇸
Emory University School of Medicine/Winship Cancer Institute SC, Atlanta, Georgia, United States
🇺🇸
Los Angeles Hematology/Oncology Medical Group Onc Dept., Los Angeles, California, United States
🇺🇸
Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp, Dallas, Texas, United States

and more 21 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy